Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07529626 | Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer(MIND-PANC) | recruiting | — | 320 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07605819 | Pancreatic Cancer Screening Using the Enzeavour Assay in Japan(ENZEAVOUR FS) | recruiting | N/A | 10,000 | Cosomil, Inc.INDUSTRY | 1 | Jun 26, 2026 |
| clinicaltrials |
| NCT07670286 | Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia | recruiting | — | 500 | Peking Union Medical College HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07671339 | A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06205849 | Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer | recruiting | Phase 1 | 18 | University of California, San DiegoOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06755359 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer | recruiting | N/A | 40 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07387263 | Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing | recruiting | N/A | 180 | Unity Health TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07660627 | Determining Minimal Residual Disease Using ctDNA Deep Sequencing(CIT-SEQ) | recruiting | N/A | 34 | Masaryk Memorial Cancer InstituteOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03536793 | Tumour Regulatory Molecules in Early Pancreatic Cancer Detection(TEM-PAC) | recruiting | — | 180 | Hull University Teaching Hospitals NHS TrustOTHER_GOV | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04678648 | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | recruiting | Phase 1 | 134 | RasCal Therapeutics, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05929885 | Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients | recruiting | Phase 2 | 50 | National Cancer Centre, SingaporeOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07432633 | [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 1 / Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05346536 | Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)(CTC-AXL-PANC) | recruiting | N/A | 63 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04616131 | Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy | recruiting | — | 500 | Northwestern UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07656571 | Indocyanine Green-Guided Versus Standard Laparoscopic Distal Pancreatectomy for Pancreatic Body and Tail Lesions(ICG-LDP) | recruiting | N/A | 72 | Alexandria UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05093231 | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 20 | Cambridge University Hospitals NHS Foundation TrustOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07219238 | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | recruiting | Phase 2 / Phase 3 | 175 | GE HealthcareINDUSTRY | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT05657743 | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) | recruiting | N/A | 15 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06026943 | Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer | recruiting | N/A | 15 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06479239 | Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer(Panc 002) | recruiting | Phase 1 / Phase 2 | 23 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649928 | A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer | recruiting | Early Phase 1 | 24 | Ruijin HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651358 | A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy | recruiting | N/A | 30 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03711890 | Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer | recruiting | N/A | 75 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04048278 | Lidocaine Infusion in Pancreatic Cancer | recruiting | Early Phase 1 | 46 | University of Illinois at ChicagoOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07589569 | An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer | recruiting | Phase 2 | 92 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06278454 | Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases | recruiting | Phase 1 | 58 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07199764 | Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer(IGNITE) | recruiting | Phase 2 | 100 | University of PennsylvaniaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06849063 | Assessment of the Prognosis of Pancreatic Cancer Patients Using 3D MRE | recruiting | — | 200 | Yu ShiOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07226856 | BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | recruiting | Phase 2 | 43 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT06158139 | Autologous CAR-T Cells Targeting B7-H3 in PDAC | recruiting | Phase 1 | 27 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06790602 | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma(SWITCH) | recruiting | Phase 2 | 43 | University of California, San DiegoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07145450 | Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC | recruiting | Phase 1 / Phase 2 | 96 | Anocca ABOTHER_GOV | 4 | Jun 8, 2026 | clinicaltrials |
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery | recruiting | Phase 3 | 288 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07629609 | BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer(BEFAST) | recruiting | Phase 2 | 90 | Barbara Malene FischerOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07627711 | Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma(DUAL-NK-PDAC) | recruiting | Phase 1 / Phase 2 | 42 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06770452 | HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients | recruiting | Phase 2 | 133 | Zhejiang UniversityOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07483554 | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors | recruiting | Phase 2 | 389 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03823144 | Intravital Microscopy in Human Solid Tumors | recruiting | N/A | 85 | Mayo ClinicOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07619391 | MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer | recruiting | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06122896 | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals | recruiting | Early Phase 1 | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | May 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2026source: clinicaltrials